Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics (Q35618430)

9 August 2017

Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics (English)

1 reference

9 August 2017

Sidney H Kennedy

1

1 reference

PubMed ID

14700011

9 August 2017

Raymond W Lam

series ordinal

2

1 reference

9 August 2017

1 January 2003

1 reference

9 August 2017

1 reference

9 August 2017

5 Suppl 2

1 reference

9 August 2017

36-47

1 reference

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

9 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Relapse of depression in primary care. Rate and clinical predictors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Anxiety as a correlate of response to the acute treatment of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

The long-term natural history of the weekly symptomatic status of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Is bipolar disorder still underdiagnosed? Are antidepressants overutilized?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

An Inventory for Measuring Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Combining Antidepressants for Treatment-Resistant Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Major tranquillisers used as antidepressants. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Role of risperidone in bipolar II: an open 6-month study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

A novel augmentation strategy for treating resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Methylphenidate augmentation of citalopram in elderly depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Medication resistance and clinical response to electroconvulsive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Modest adjunctive benefit with transcranial magnetic stimulation in medication-resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Follow-up and family study of anxious depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Clinical practice guidelines: praise and problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Anxiety syndromes as epiphenomena of primary major depression: outcome and familial psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Anxious and nonanxious depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

What role do atypical antipsychotic drugs have in treatment-resistant depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Olanzapine response in psychotic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Modafinil augmentation of antidepressant treatment in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

Resistance to antidepressant medications and short-term clinical response to ECT

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00058.X

10.1111/J.1399-2406.2003.00058.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14700011